SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Digestive Disorder

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2148456

Cover Image

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2148456

Irritable Bowel Syndrome (IBS) Therapeutics

PUBLISHED:
PAGES: 348 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Team License: Up to 10 users)
USD 11115
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Irritable Bowel Syndrome (IBS) Therapeutics Market to Reach US$6.4 Million by 2032

The global market for Irritable Bowel Syndrome (IBS) Therapeutics estimated at US$3.8 Million in the year 2025, is expected to reach US$6.4 Million by 2032, growing at a CAGR of 7.6% over the analysis period 2025-2032. IBS-C Type, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.8 Million by the end of the analysis period. Growth in the IBS-D Type segment is estimated at 9.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Million While China is Forecast to Grow at 11.3% CAGR

The Irritable Bowel Syndrome (IBS) Therapeutics market in the U.S. is estimated at US$1.0 Million in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Million by the year 2032 trailing a CAGR of 11.3% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Irritable Bowel Syndrome (IBS) Therapeutics Market - Key Trends and Drivers Summarized

Irritable Bowel Syndrome (IBS) is a prevalent gastrointestinal disorder that affects the large intestine, manifesting symptoms such as abdominal pain, bloating, constipation, and diarrhea. Although not life-threatening, IBS substantially reduces quality of life and imposes a significant economic burden on healthcare systems. Historically, IBS was diagnosed by exclusion, but advancements now allow for quicker identification using criteria such as the Rome III, alongside a detailed medical history and physical examination. This disorder is characterized by chronic abdominal discomfort or pain associated with altered bowel habits, with symptoms needing to have started at least six months before diagnosis and occurring at least three days per month in the last three months. This contemporary understanding helps streamline the diagnostic process, avoiding unnecessary and costly tests, especially in younger patients presenting typical IBS symptoms without severe indicators such as unintentional weight loss or anemia.

The treatment landscape for IBS has diversified over the years, moving beyond conventional options like fiber supplements and muscle relaxants to include tailored treatments based on predominant symptoms-ranging from dietary changes and probiotics to antibiotics and combinations of medications such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). There's a shifting emphasis from antispasmodics, due to their limited efficacy and significant side effects, towards TCAs and SSRIs that modulate pain perception both centrally and peripherally. Additionally, dietary management, particularly the reduction of high-FODMAP foods, and the use of probiotics have become integral in managing bloating and other digestive discomforts. For constipation and diarrhea predominant IBS, newer medications like lubiprostone and linaclotide for constipation, and alosetron and rifaximin for diarrhea, are enhancing therapeutic outcomes by targeting specific functional symptoms of the disorder.

Several factors are driving growth in the IBS therapeutics market. Advances in diagnostic technologies, such as the implementation of the Rome IV guidelines, have refined the accuracy of IBS diagnosis, fostering a more targeted therapeutic approach. There is also an increased consumer awareness and engagement, partly fueled by media, patient advocacy groups, and healthcare initiatives, which heighten demand for effective treatments. The integration of digital health solutions, including telehealth services and mobile health applications for symptom tracking and management, supports continuous patient monitoring and personalized treatment adjustments. Furthermore, the development of targeted pharmacological agents aimed at modifying gut flora, and expanding insurance coverage and healthcare policies that favor newer, albeit more costly, treatments are enhancing access to these therapies. These advancements, alongside active patient support programs and evolving regulatory landscapes, are essential for meeting the growing needs of IBS patients and improving their overall management and quality of life.

SCOPE OF STUDY:

The report analyzes the Irritable Bowel Syndrome (IBS) Therapeutics market by the following Segments, and Geographic Regions/Countries:

Segments:

Type (IBS-C Type, IBS-D Type); Drug Class (Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class, Other Drug Classes); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Allergan PLC
  • Astellas Pharma, Inc.
  • IM HealthScience
  • Mallinckrodt Pharmaceuticals
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co., Ltd.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Show more
Product Code: MG6796

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Irritable Bowel Syndrome (IBS) Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 12 Players Worldwide in 2026 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of IBS Propels Demand for Effective Therapeutics
    • Advances in Gut Microbiome Research Strengthen Business Case for Novel IBS Treatments
    • Increasing Awareness and Diagnosis of IBS Expands Addressable Market Opportunity
    • Focus on Personalized Medicine Drives Adoption of Tailored IBS Therapeutics
    • Growing Geriatric Population and Associated Digestive Disorders Spur Growth in IBS Therapeutics Market
    • Introduction of Combination Therapies Throws the Spotlight on Enhanced Treatment Efficacy
    • Advances in Probiotics and Prebiotics Propel Development of Innovative IBS Treatments
    • Increasing Focus on Non-Pharmacological Therapies: Here's the Story of Complementary Treatment Approaches
    • Focus on Minimizing Side Effects and Improving Quality of Life Sustains Demand for Novel Therapies
    • Growing Adoption of Digital Health Solutions Expands Access to IBS Treatment and Management
    • Advances in Molecular Diagnostics Propel Growth in Precision Medicine for IBS
    • Expansion of Telemedicine and Remote Patient Monitoring Drives Market Adoption
    • Advances in Drug Delivery Systems Propel Development of Novel IBS Therapeutics
    • Rising Prevalence of Lifestyle-Related Risk Factors Expands Addressable Market Opportunity
    • Development of Biosimilars and Generics Throws the Spotlight on Affordable Treatment Options
    • Increasing Focus on Integrative and Complementary Therapies Drives Demand for Comprehensive IBS Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for IBS-C Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for IBS-C Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for IBS-C Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for IBS-D Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for IBS-D Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for IBS-D Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Xifaxan Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Xifaxan Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Xifaxan Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Linzess / Constella Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Linzess / Constella Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Linzess / Constella Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Viberzi Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Viberzi Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Viberzi Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Amitiza Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Amitiza Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Amitiza Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 36: USA Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 37: USA 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 38: USA Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 39: USA Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 40: USA 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 41: USA Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 42: USA Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 43: USA 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Canada Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 46: Canada 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 48: Canada Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 49: Canada 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Canada Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 52: Canada 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • JAPAN
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Japan Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 55: Japan 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Japan Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 58: Japan 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Japan Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 61: Japan 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • CHINA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 63: China Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 64: China 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 65: China Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 66: China Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 67: China 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 68: China Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 69: China Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 70: China 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • EUROPE
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 73: Europe 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 75: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 76: Europe 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 79: Europe 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 82: Europe 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • FRANCE
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 84: France Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 85: France 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 86: France Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 87: France Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 88: France 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 89: France Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 90: France Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 91: France 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • GERMANY
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Germany Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 94: Germany 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Germany Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 97: Germany 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Germany Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 100: Germany 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Italy Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 103: Italy 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Italy Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 106: Italy 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Italy Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 109: Italy 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 111: UK Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 112: UK 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 113: UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 114: UK Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 115: UK 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 116: UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 117: UK Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 118: UK 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Spain Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 121: Spain 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Spain Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 124: Spain 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Spain Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 127: Spain 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Russia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 130: Russia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Russia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 133: Russia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Russia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 136: Russia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 139: Rest of Europe 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 142: Rest of Europe 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 145: Rest of Europe 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 148: Asia-Pacific 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 151: Asia-Pacific 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 154: Asia-Pacific 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 157: Asia-Pacific 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Australia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 160: Australia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Australia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 163: Australia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Australia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 166: Australia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • INDIA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 168: India Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 169: India 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 170: India Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 171: India Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 172: India 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 173: India Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 174: India Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 175: India 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 177: South Korea Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 178: South Korea 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 180: South Korea Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 181: South Korea 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 183: South Korea Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 184: South Korea 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 196: Latin America 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 198: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 199: Latin America 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 202: Latin America 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 205: Latin America 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Argentina Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 208: Argentina 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Argentina Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 211: Argentina 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Argentina Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 214: Argentina 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Brazil Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 217: Brazil 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Brazil Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 220: Brazil 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Brazil Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 223: Brazil 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Mexico Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 226: Mexico 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Mexico Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 229: Mexico 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Mexico Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 232: Mexico 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 235: Rest of Latin America 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 238: Rest of Latin America 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 241: Rest of Latin America 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 244: Middle East 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 246: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 247: Middle East 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 250: Middle East 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 253: Middle East 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Iran Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 256: Iran 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Iran Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 259: Iran 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Iran Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 262: Iran 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Israel Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 265: Israel 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Israel Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 268: Israel 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Israel Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 271: Israel 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 274: Saudi Arabia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 277: Saudi Arabia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 280: Saudi Arabia 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 282: UAE Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 283: UAE 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 285: UAE Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 286: UAE 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 288: UAE Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 289: UAE 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 292: Rest of Middle East 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 295: Rest of Middle East 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 298: Rest of Middle East 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • AFRICA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Africa Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-C Type and IBS-D Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 301: Africa 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-C Type and IBS-D Type for the Years 2020, 2026 & 2032
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Africa Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 304: Africa 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Xifaxan Drug Class, Linzess / Constella Drug Class, Viberzi Drug Class, Amitiza Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Africa Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 307: Africa 13-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!